Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Leukemia and Lymphoma

• Publication date

  2015-02-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.3109/10428194.2014.922180PMID 24828872PMCID PMC4868500
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53−/− mouse model and primary human leukemia cells

  2014cited by this paper
• High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

  2013cited by this paper
• Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL.

  2013cited by this paper
• Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy.

  2012cited by this paper
• WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.

  2012cited by this paper
• The Metabolic Signature of CLL: Enhanced Glucose Metabolism in A Subset of High-Risk CLL Patients

  2012cited by this paper
• Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.

  2012cited by this paper
• Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.

  2012cited by this paper
• Metformin in cancer: translational challenges.

  2012cited by this paper
• Investigating metformin for cancer prevention and treatment: the end of the beginning.

  2012cited by this paper
• Targeting cancer metabolism: a therapeutic window opens

  2011cited by this paper
• Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality

  2011cited by this paper
• Chronic Lymphocytic Leukemia: An Update on Biology and Treatment

  2011cited by this paper
• Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Metformin induces Rab4 through AMPK and modulates GLUT4 translocation in skeletal muscle cells

  2011cited by this paper
• The treatment of relapsed refractory chronic lymphocytic leukemia.

  2011cited by this paper
• Choosing first-line therapy for chronic lymphocytic leukemia

  2011cited by this paper
• Selection of reference genes for quantitative polymerase chain reaction studies in purified B cells from B cell chronic lymphocytic leukaemia patients

  2010cited by this paper
• Glucose Transporter Expression of an Esophageal Gastrointestinal Tumor Detected by F-18 FDG PET/CT

  2010cited by this paper
• Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation

  2010cited by this paper
• Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

  2009cited by this paper
• Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

  2009cited by this paper
• Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

  2009cited by this paper
• Targeting Glucose Consumption and Autophagy in Myeloma with the Novel Nucleoside Analogue 8-Aminoadenosine*

  2009cited by this paper
• Targeting the Warburg effect in hematological malignancies: from PET to therapy

  2009cited by this paper
• F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

  2009cited by this paper
• Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model

  2009cited by this paper
• Tumor suppressors and cell metabolism: a recipe for cancer growth.

  2009cited by this paper
• B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

  2009cited by this paper
• Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model

  2008cited by this paper
• A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death

  2008cited by this paper
• mTORC1 promotes survival through translational control of Mcl-1

  2008cited by this paper
• A pivotal role for Mcl-1 in Bortezomib-induced apoptosis

  2008cited by this paper
• Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1.

  2007cited by this paper
• Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

  2007cited by this paper
• Glycolysis inhibition for anticancer treatment

  2006cited by this paper
• Effects of HIV Protease Inhibitor Ritonavir on Akt-Regulated Cell Proliferation in Breast Cancer

  2006cited by this paper
• Matrix metalloproteinase-2 contributes to cancer cell migration on collagen.

  2005cited by this paper
• Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.

  2005cited by this paper
• Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.

  2005cited by this paper
• Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes.

  2004cited by this paper
• Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.

  2004cited by this paper
• Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study.

  2004cited by this paper
• HIV-1 Protease Inhibitor, Ritonavir

  2004cited by this paper
• Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

  2002cited by this paper
• The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy*

  2000influential reference
• Genistein Is a Natural Inhibitor of Hexose and Dehydroascorbic Acid Transport through the Glucose Transporter, GLUT1 (*)

  1996cited by this paper
• The pentose cycle. Control and essential function in HeLa cell nucleic acid synthesis.

  1980influential reference
• Brief Note: The Use of Desoxyribonuclease As an Aid to the Identification of Primitive White Blood Cells

  1961cited by this paper
• On the origin of cancer cells.

  1956cited by this paper
• [Origin of cancer cells].

  1956cited by this paper

• The Critical Role of Adipocytes in Leukemia

  2025cites this paper
• Ritonavir and DNA Damage: A New Perspective on an Old Drug

  2025cites this paper
• Drug Repurposing as an Effective Drug Discovery Strategy: A Critical Review

  2025cites this paper
• Inhibition of human DNA alkylation damage repair enzyme ALKBH2 by HIV protease inhibitor ritonavir.

  2024cites this paper
• Overcoming Chemotherapy Resistance in Metastatic Cancer: A Comprehensive Review

  2024cites this paper
• Research Progress on the Use of Metformin in Leukemia Treatment

  2024influential citation
• Molecular Secrets Revealed: How Diabetes may be Paving the Way for Leukemia

  2024cites this paper
• Neurotoxicity of the antineoplastic drugs: “Doxorubicin” as an example

  2024cites this paper
• The Metabolism and Immune Environment in Diffuse Large B-Cell Lymphoma

  2023cites this paper
• Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges

  2023cites this paper
• Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects

  2023cites this paper
• Glucose transporter 4: Insulin response mastermind, glycolysis catalyst and treatment direction for cancer progression.

  2023cites this paper
• Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma

  2023cites this paper
• Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review

  2023cites this paper
• Targeted Drug Delivery for Chronic Lymphocytic Leukemia

  2022cites this paper
• Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?

  2022cites this paper
• AMPKα2/HNF4A/BORIS/GLUT4 pathway promotes hepatocellular carcinoma cell invasion and metastasis in low glucose microenviroment.

  2022cites this paper
• Single-Cell Metabolomics in Hematopoiesis and Hematological Malignancies

  2022cites this paper
• Targeting metabolic reprogramming in chronic lymphocytic leukemia

  2022cites this paper
• Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma.

  2022cites this paper
• Interactions between HIV protease inhibitor ritonavir and human DNA repair enzyme ALKBH2: a molecular dynamics simulation study

  2022cites this paper
• Mitochondrial oxidative phosphorylation is dispensable for survival of CD34+ chronic myeloid leukemia stem and progenitor cells

  2022cites this paper
• The Importance of Cellular Metabolic Pathways in Pathogenesis and Selective Treatments of Hematological Malignancies

  2021cites this paper
• Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment?

  2021cites this paper
• Protein kinase C‐β‐dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia

  2021cites this paper
• Metformin - its anti-cancer effects in hematologic malignancies

  2021cites this paper
• Elucidation of the molecular interactions that enable stable interaction between HIV protease inhibitor ritonavir and human DNA repair enzyme ALKBH2: a molecular dynamics simulation study

  2021cites this paper
• Lipid uptake in chronic lymphocytic leukemia.

  2021cites this paper
• Mitochondrial Transfer and Regulators of Mesenchymal Stromal Cell Function and Therapeutic Efficacy

  2020cites this paper
• Berberine affects mitochondrial activity and cell growth of leukemic cells from chronic lymphocytic leukemia patients

  2020cites this paper
• Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma.

  2020cites this paper
• Cancer Cell Metabolism: Solid Tumor Versus Nonsolid Tumor

  2020cites this paper
• Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know?

  2019cites this paper
• Tumor Metabolism as a Regulator of Tumor–Host Interactions in the B-Cell Lymphoma Microenvironment—Fueling Progression and Novel Brakes for Therapy

  2019cites this paper
• Metformin and blood cancers

  2018cites this paper
• Altered Metabolism of Leukemic Cells: New Therapeutic Opportunity.

  2018cites this paper
• Targeting ulcerative colitis by suppressing glucose uptake with ritonavir

  2018cites this paper
• Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes

  2018cites this paper
• Drug Repurposing of Metabolic Agents in Malignant Glioma

  2018cites this paper
• Metformin, an Anti-diabetic Drug to Target Leukemia

  2018influential citation
• The Typical Metabolic Modifiers Conferring Improvement in Cancer Resistance.

  2017cites this paper
• Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer.

  2017cites this paper
• Drug repurposing in cancer.

  2017cites this paper
• Effects of metformin on proliferation and apoptosis of human megakaryoblastic Dami and MEG-01 cells.

  2017cites this paper
• Development of GLUT4-selective antagonists for multiple myeloma therapy.

  2017cites this paper
• Role of multifaceted regulators in cancer glucose metabolism and their clinical significance

  2016cites this paper
• Metabolism pathways in chronic lymphocytic leukemia

  2016cites this paper
• Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs

  2016cites this paper
• In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy*

  2015cites this paper
• TARGETING LEUKEMIA CELL METABOLISM

  2015cites this paper
• Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells

  2015cites this paper
• Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

  2014cites this paper